BPC 157 - Zyvex Pharmaceuticals

Frequently Asked Questions

• What is BPC 157 and what does it do?

  BPC 157 (Body Protective Compound 157) is a synthetic pentadecapeptide - a chain of 15 amino acids derived from a protein found in human gastric juice. It was identified by researchers studying the stomach's natural ability to protect and repair its own lining, and the isolated peptide sequence was found to have tissue-healing effects far beyond the gut. BPC 157 accelerates healing of tendons, ligaments, muscle, bone, and the gastrointestinal tract by promoting angiogenesis (new blood vessel growth), upregulating growth factor receptors at injury sites, increasing collagen synthesis, and modulating nitric oxide pathways to improve blood flow to damaged tissue. It does not build muscle or raise hormone levels the way anabolic steroids do - its role is repair and recovery. Athletes and bodybuilders use it primarily to speed healing of connective tissue injuries that are the common consequence of heavy training: tendinopathy, ligament sprains, muscle tears, and gut damage from chronic NSAID use.

• Is BPC 157 legal to buy and use?

  BPC 157 is not a controlled substance in the United States - it is not scheduled under the Controlled Substances Act and is not classified as an anabolic steroid. It is sold legally as a research peptide. It is not FDA-approved for human medical use, which means it cannot be prescribed or marketed as a drug for treating injuries in people. WADA has banned BPC 157 for competitive athletes as a prohibited peptide hormone and growth factor. The practical summary: legal to purchase as a research compound in the US, not legal for use in sanctioned competitive sport, and not a medical treatment with FDA approval. Athletes use it based on preclinical evidence and anecdotal reports, with awareness that human clinical trial data is limited.

• What is the correct BPC 157 dosage?

  The standard protocol is 200-500 mcg per day. Most users start at 200-250 mcg daily for moderate injuries and increase to 500 mcg for severe or slow-healing injuries. To calculate doses from a reconstituted vial: add 2 mL of bacteriostatic water to the 5 mg vial to get a concentration of 2,500 mcg per mL (2.5 mcg per microliter). At this concentration, 200 mcg = 0.08 mL and 500 mcg = 0.2 mL per injection. Some athletes split the daily dose into two injections (morning and evening) at the higher end of the range, though once-daily dosing is common and effective. Cycle length is 4-8 weeks, or until the injury has healed to functional capacity. There is no known need for a post-cycle recovery period - BPC 157 does not suppress the endocrine system.

• Where should I inject BPC 157 - near the injury or anywhere?

  Both approaches are used and serve different purposes. Local injection (subcutaneous or intramuscular near the injury site) is the preferred method for specific localized injuries - a damaged tendon, a muscle tear, a joint problem. The injection does not have to be directly into the injury: subcutaneous injection within 5-10 cm of the injured area concentrates the peptide's effects where they are needed. This is the recommended approach for tendinopathy, ligament sprains, and muscle strains. Systemic injection (subcutaneous into abdominal fat, away from any specific injury) is used when the goal is gut healing, general anti-inflammatory effect, or when the injury location is difficult to inject locally. In practice, many athletes use local injection for the primary injury and add a systemic dose for GI support simultaneously. For gut-specific conditions, systemic subcutaneous injection is the only practical option.

• How long does BPC 157 take to work?

  Most users report noticeable pain reduction and improved function within 1-2 weeks of daily dosing. The speed of response depends on the injury type and severity. Soft tissue injuries - tendinopathy, mild muscle strains, gut inflammation - typically show early improvement within 7-14 days. More structural injuries like ligament sprains or significant muscle tears take longer: functional improvement is usually measurable at 3-4 weeks, with full recovery extending to 6-8 weeks of consistent dosing. GI conditions often respond fastest - some users report symptom improvement within the first week. BPC 157 is not a painkiller that masks symptoms; the pain reduction that occurs reflects actual tissue repair rather than suppression of the inflammatory signal, which is why the timeline tracks the healing process rather than providing immediate relief.

• How do I combine BPC 157 and TB-500?

  BPC 157 and TB-500 (Thymosin Beta 4) have complementary mechanisms that make them the most established peptide healing stack in bodybuilding. BPC 157 acts primarily at the local injury site - it drives tendon-to-bone healing, collagen synthesis, and angiogenesis at the damaged tissue. TB-500 operates more systemically - it promotes cell migration, reduces inflammation throughout the body, and improves muscle fiber flexibility. Running them together addresses healing from both local and systemic angles simultaneously. The standard protocol: BPC 157 at 250-500 mcg per day via local subcutaneous injection near the injury site, combined with TB-500 at 2-2.5 mg twice per week via systemic subcutaneous injection (abdominal fat). Run both for 4-8 weeks. There is no known negative interaction between them - the combination is widely used because the mechanisms are additive, not redundant. For acute injuries, this stack consistently outperforms either compound used alone based on anecdotal evidence across bodybuilding communities.

• Is BPC 157 FDA approved?

  No. BPC 157 has not completed human clinical trials and is not FDA-approved for any medical use. It is sold as a research compound. The evidence base for BPC 157 consists of extensive animal studies (rodent and some larger animal models) showing consistent tissue-healing effects, plus a substantial body of anecdotal human reports from athletes. The gap between the preclinical evidence and FDA approval is not a question of safety concerns - the animal data is generally favorable and human reports rarely document serious adverse effects - but a question of clinical trial completion, which has not occurred. This means BPC 157 cannot be prescribed by a physician for injury treatment, cannot be marketed as a therapeutic drug, and is used by athletes who are self-administering a research compound based on available evidence rather than approved medical guidance.

• What are the side effects of BPC 157?

  BPC 157 has a favorable safety profile in animal studies and a low rate of serious adverse effects in human anecdotal use. The most commonly reported side effects are injection site reactions - mild redness, swelling, or discomfort that typically resolves within 24 hours. Some users report mild nausea or lightheadedness after injection, particularly at 500 mcg doses, which often resolves after the first few injections and can be minimized by injecting after eating rather than on an empty stomach. One theoretical concern: BPC 157 promotes angiogenesis (new blood vessel formation), and some researchers have raised the possibility that this could support tumor vascularity in individuals with pre-existing malignancies. No evidence of tumor promotion in healthy individuals has been documented in animal studies. Anyone with a current or recent history of cancer should not use BPC 157. Long-term effects of extended human use are unknown due to the absence of clinical trial data - use is recommended in defined 4-8 week cycles for specific injuries rather than indefinite continuous administration.